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Abstract
Background: Recently, we demonstrated that suramin, a compound that inhibits the interaction of multiple cytokines/
growth factors with their receptors, inhibits activation and proliferation of renal interstitial fibroblasts, and attenuates the
development of renal interstitial fibrosis in the murine model of unilateral ureteral obstruction (UUO). However, it remains
unclear whether suramin can alleviate glomerular and vascular lesions, which are not typical pathological changes in the
UUO model. So we tested the efficacy of suramin in the remnant kidney after 5/6 nephrectomy, a model characterized by
the slow development of glomerulosclerosis, vascular sclerosis, tubulointerstitial fibrosis and renal inflammation, mimicking
human disease.
Methods/Findings: 5/6 of normal renal mass was surgically ablated in male rats. On the second week after surgery, rats
were randomly divided into suramin treatment and non-treatment groups. Suramin was given at 10 mg/kg once per week
for two weeks. In the remnant kidney of mice receiving suramin, glomerulosclerosis and vascular sclerosis as well as
inflammation were ameliorated. Suramin also attenuated tubular expression of two chemokines, monocyte chemoat-
tractant protein-1 and regulated upon expression normal T cell expressed and secreted (RANTES). After renal mass ablation,
several intracellular molecules associated with renal fibrosis, including NF-kappaB p65, Smad-3, signal transducer and
activator of transcription-3 and extracellular regulated kinase 1/2, are phosphorylated; suramin treatment inhibited their
phosphorylation. Futhermore, suramin abolished renal ablation-induced phosphorylation of epidermal growth factor
receptor and platelet derived growth factor receptor, two receptors that mediate renal fibrosis.
Conclusions and Significance: These findings suggest that suramin attenuates glomerular and vascular injury and reduces
inflammatory responses by suppression of multiple growth factor receptor-mediated profibrotic signaling pathways.
Therefore, suramin may be a useful drug in preventing the fibrosis and sclerosis that characterizes progression of chronic
kidney disease.
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Introduction
The pathogenesis of chronic kidney disease (CKD) in most cases
involves a complex interaction of hemodynamic and inflammatory
processes that leads to glomerular and vascular sclerosis and
tubulointerstitial scarring with subsequent progression toward ESRD.
Although therapeutic interventions such as the blockade of the rennin-
angiotensin-aldosteronesystemandimmunosuppressivedrugsslowthe
progression of renal disease and promote renoprotective effects in
experimentalanimalmodels[1,2]andinhumans[3,4],thesestrategies
cannot halt the progression of renal fibrosis and scarring. The
development and progression of renal fibrosis is primarily involved in
thedifferentiationofrenalfibroblastsintomyofibroblastsandinfiltration
of inflammatory cells, regulated by numerous cytokines and growth
factors. Thus a therapeutic intervention that blocks the activation of
multiple cytokine and growth factor receptors might improve
antifibrotic effects and help slow progression of chronic nephropathies.
Suramin, a FDA-approved drug that inhibits the interaction of
multiple cytokines and growth factors with their receptors
[5,6,7,8,9], may represent a novel therapeutic option for blocking
fibrogenesis. This drug was Initially developed as a treatment for
trypanosomiaisis and selected malignancies and metastatic diseases
[5,6,7,8,9]. Recently, several studies have shown that administra-
tion of suramin protects against the development of muscle and
liver fibrosis in animal models [10,11]. By using a mouse model of
unilateral urethral obstruction (UUO), we also demonstrated that
suramin is effective in attenuating renal interstitial fibrosis [12,13].
This protective effect of suramin was further confirmed in a rat
model of remnant kidney disease as indicated by preservation of
renal tissue architecture, prevention of progressive renal interstitial
fibrosis and improvement of renal function [12]. However, it
remains unclear whether suramin is able to attenuate glomerular
and vascular sclerosis as well as inflammation, in particular,
macrophage infiltration in the remnant kidney.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e36194The remnant kidney after 5/6 nephrectomy is a classic model
that mostly mimics CKD in humans [14,15]. Histological studies
of remnant kidney tissue have indicated a complex response
consisting primarily of three steps: a hypertrophic phase, a
quiescent phase with minimal histological alterations, and finally
the development of segmental glomerular sclerosis and tubuloin-
terstitial fibrosis [16,17]. Hyperfiltration has been identified as a
significant contributor to the hypertrophy and glomerulosclerosis
and macrophages play a key role in renal injury induced by
glomerular hyperfiltration following reduction of kidney mass by
ablation [18]. Macrophages localize to glomeruli and the
interstitium via interactions with several chemokines, including
monocyte chemo attractant protein-1(MCP-1), and regulated
upon activation, normal upon expression normal T cell expressed
and secreted (RANTES) [18,19,20]. This proinflammatory
microenvironment promotes renal scarring [14,15]. In the kidney,
tubular epithelial cells are considered to be a prominent source of
chemokines [21]. MCP-1 and RANTES are two key chemokines
that recruit monocytes/macrophages to the kidney [22,23].
Many mediators, including transformation growth factor-beta1
(TGF-beta1), epidermal growth factor (EGF), and platelet-derived
growthfactor(PDGF),arealsoupregulatedinglomeruliandtubules
and are believed to be involved in the progression of glomerular
sclerosis and tubulointerstitial fibrosis [24,25,26]. The interaction of
cytokines/growth factors with their receptors initiates different
signaling pathways, leading to the activation of multiple transcrip-
tional factors such as NF-kappaB and signal transducer and
activator of transcription 3 (STAT3) that regulate various genes
related to the activation of renal fibroblasts and initiation of
inflammation [27]. In addition, activation of smad3, a key
intracellular mediator in TGF-beta signaling, is induced in different
models of renal fibrosis [12]. Recently, we have shown that suramin
treatment can block phosphorylation of EGF receptor (EGFR),
PDGF receptor (PDGFR), and smad3, However, it is unknown
whether suramin is able to interfere with those signaling pathways
and inactivation of NF-kappaB in the remnant kidney.
In this study, we examined the effect of suramin on glomerular
and vascular sclerosis, and inflammatory cell infiltration in the
remnant kidney model. Further, we investigated the effect of
suramin on the expression of MCP-1 and RANTES and the
activation of growth factor receptors/intracellular signaling path-
ways associated with the development of progressive renal injury.
Figure 1. Effect of suramin on glomerular sclerosis in rat remnant kidney. (A) Photomicrographs Photomicrographys (4006) illustrating
periodic acid-Schiff-stained sections of kidney tissue on week 4 after various treatments as indicated. (B) Photomicrographs (4006) illustrating
trichrome stained kidney tissue on week 4 after various treatments. RK, remnant kidney.
doi:10.1371/journal.pone.0036194.g001
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Suramin inhibits glomerular and vascular sclerosis in rat
remnant kidneys
We recently showed that suramin prevented progressive renal
injury as demonstrated by inhibition of a rise in 24 hour-protein
excretion and a rise in serum creatinine by preserving renal tissue
architecture and preventing the development of renal interstitial
fibrosis in the rat model of remnant kidney disease [12]. As
glomerular and vascular sclerosis are also two major pathogenetic
changes in the model of remnant kidneys, we further examined the
effectofsuraminonthoseevents.AsshowninFigure1and2,after4-
weeks of renal ablation, 15% of glomeruli were damaged and
displayed segmental and focal solidification and sclerosis of the
glomerular tuft (Fig. 1A). Forty percent of renal arteries also show an
onion skin-like change, indicating vascular sclerosis in the remnant
kidney (Fig. 2A). By comparison, very few sclerotic glomeruli and
arterieswereobserved inthekidneyofanimalsthatreceivedsuramin
treatment. There were no obvious pathological changes in the
kidney of both sham and suramin alone-treated animals.
Masson trichrome staining showed increased deposition of
collagen fibrils in glomeruli and blood vessels following the 5/6
renal ablation (Fig. 1B, 2B). Administration of suramin diminished
deposition of collagen fibrils in glomeruli and blood vessels.
Perivascular collagen fibril deposition around small arteries also
increased, butwassuppressed bysuramintreatment. Notably,inthe
normal kidney, expression of ECM protein was seen in perivascular
areas (positive onMassontrichome staining)and was notaffected by
suramin (Fig. 2B). This data, together with our previous observation
that suramin inhibits the development of renal interstitial fibrosis,
suggests that suramin application has renoprotective properties and
is able to prevent the development of fibrotic lesions in all areas
including glomeruli and arteries in the remnant kidney.
Suramin reduces infiltration of monocytes/macrophages
to the remnant kidney
Kidney fibrosis is almost always preceded by and closely
associated with chronic interstitial inflammation [23,28,29,30].
Macrophage infiltration and proliferation functionally contributes
to the fibroticprocess after injury[31,32]. To determinethe effect of
Figure 2. Effect of suramin on vascular sclerosis in rat remnant kidney. (A) Photomicrographs (4006) illustrating periodic acid-Schiff-stained
sections of kidney tissue on week 4 after various treatments as indicated. (B) Photomicrographs (4006) illustrating trichrome stained kidney tissue on
week 4 after various treatments. RK, remnant kidney.
doi:10.1371/journal.pone.0036194.g002
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detects active monocytes/macrophages. Figure 3A showed that
monocyte/macrophage infiltration was increased in the remnant
kidneycompared with the sham-operated kidney(Fig. 3A). Suramin
treatment significantly reduced the number of monocytes/macro-
phages (Fig. 3A). Next, we determined the expression levels of ED-1
in the kidney tissue by immunoblot analysis. ED1 was detected in
the normal kidney, and its levels were increased in the remnant
kidney. Suramin treatment also reduced ED1 expression to the
basal level in the tissue of the remnant kidney. This data, together
with our recent observation that neutrophil numbers are reduced in
the obstructed kidney treated with suramin [12], suggest that
suraminisalsoabletosuppressinfiltration ofinflammatorycellsinto
the damaged kidney in chronic injury.
Suramin attenuates the expression of MCP-1 and RANTES
after renal ablation
MCP-1 and RANTES are two chemokines that play an
important role in attracting inflammatory cells including mono-
cytes/macrophages to sites of inflammation, and contributes to
renal interstitial fibrosis [33,34]. In the kidney, tubular epithelial
cells (TEC) are considered a prominent source of chemokines [21].
Thus, we examined their expression by immuohistochemistry. A
low level of MCP-1 was detected in the sham-operated with or
without treatment with suramin (Fig. 4A). However, abundant
expression of MCP-1 was detected in the remnant kidney,
primarily localized in tubular cells (Fig. 4B). Administration of
suramin significantly decreased MCP-1 expression levels
(Fig. 4A,B). A basal level of RANTES protein was observed in
Figure 3. Effect of suramin on monocytes/microphage accumulation in rat remnant kidney. (A) Photomicrographs (4006) illustrating
ED1-stained sections of kidney tissue on week 4 after various treatments as indicated. (B) Kidney tissue lysates were subjected to immunoblot analysis
with specific antibodies against ED1 and GAPDH. (C) ED1 staining graphic presentation of quantitative data. (D) Expression levels of ED1 was
quantified by densitometry and normalized with GAPDH. Data are represented as the mean 6 S.E.M (n=6). Means with different superscript letters
are significantly different from one another (P,0.05).
doi:10.1371/journal.pone.0036194.g003
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its expression was elevated in the remnant kidney. Like MCP-1,
RANTES was also predominantly expressed in the renal tubules
(Fig. 5A). Suramin treatment reduced its expression (Fig. 5B).
These results, in conjunction with our recent observations that
suramin inhibits expression of multiple cytokines including TGF-
beta1, TNF-alpha, Interleukin-1, ICAM-1 [12] in the model of
UUO, suggest that suramin has a strong inhibitory effect on
inflammatory responses in the renal kidney.
Suramin reduces NF-kappaB activation in the rat remnant
kidney
NF-kappaB is a ubiquitous eukaryotic transcription factor that
regulates gene expression of cytokines and enzymes involved in
controlling inflammatory responses [35]. Phosphorylation of the p65
unit of NF-kappaB initiates its activation and plays an important role
in regulating the specificity of the NF-kappaB-dependent gene
expression [36]. Suramin may regulate expression of multiple
cytokinesandchemokines,throughactivation of NF-kappaB. Totest
this hypothesis, we determined the phosphorylation of p65 NF-
kappaB in rat remnant kidney treated with/without suramin by
Western blot analysis. Figure 6 shows that the phosphorylated NF-
kappaB p65 was not detectable in the kidney of sham-operated rats,
butsignificantlyincreasedintheremnantkidney.Suramintreatment
decreased its phosphorylation. Expression of total p65 NF-kappaB
was not affected by renal ablation and suramin. These data suggest
that suramin is effective in inhibiting NF-kappaB activation in the
remnant kidney, providing the molecular basis for decreased
expression of chemokines/cytokines in the injured kidney treated
with suramin after urethral obstruction and 5/6 renal ablation.
Suramin abolishes phosphorylation of STAT3 and ERK1/2
renal ablation
In addition to NF-kappaB, STAT3 and ERK1/2 pathways also
play an important role in modulating inflammatory responses
[37,38] and renal fibroblast proliferation. We thus further
examined the effect of suramin on STAT3 and ERK1/2
phosphorylation in the remnant kidney. As shown in Fig. 7,
increased STAT3 and ERK1/2 phosphorylation (activation) was
Figure 4. Effect of suramin on MCP-1 expression in rat remnant
kidney. (A) Photomicrographs (4006) illustrating MCP-1-stained
sections of kidney tissue on week 4 after various treatments as
indicated. (B) MCP-1 staining graphic presentation of quantitative data.
Data are represented as the mean 6 S.E.M (n=6). Means with different
superscript letters are significantly different from one another (P,0.05).
doi:10.1371/journal.pone.0036194.g004
Figure5.Effectofsuramin onRANTESexpressioninratremnant
kidney. (A) Photomicrographs (4006) illustrating RANTES-stained
sections of kidney tissue on week 4 after various treatments as indicated.
(B) RANTES staining graphic presentation of quantitative data. Data are
representedas themean6S.E.M(n=6). Meanswithdifferent superscript
letters are significantly different from one another (P,0.05).
doi:10.1371/journal.pone.0036194.g005
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this response. Remnant kidney injury also increased expression
levels of total STAT3 and ERK1/2, but their expression was not
affected by suramin. This data indicates that suramin may also
suppress renal inflammation and fibroblast activation by interfer-
ing with these two signaling pathways.
Suramin abrogates phosphorylation of EGFR and PDGFR
in rat remnant kidney
Activation of intracellular signaling pathways is usually secondary
to the activation of membrane receptors. EGFR and PDGFR have
been shown to mediate activation of all three signaling pathways
described above [36,39], and they play a central role in the
activation and proliferation of renal fibroblasts leading to renal
fibrogenesis in a variety of pathological settings [40,41,42,43]. We
examined the effect of suramin on the activation of these two
receptors. PDGFR receptorand its active form(p-PDGFR) werenot
detectable in the normal kidney; however, renal ablation induced
their expression (Fig. 8). In contrast, a small amount of total EGFR
and its active form (p-EGFR) was detectable in the normal kidney,
and its expression was increased in the remnant kidney (Fig. 8).
Although administration of suramin totally blocked renal ablation-
induced phosphorylation of PDGFR and EGFR, expression of total
PDGFR and EGFRwere not affected by this treatment (Fig. 8). This
data supports the role of suramin as a potent inhibitor for multiple
growth factor receptors and also suggests the importance of PDGFR
and EGFR in mediating the anti-fibrotic action of suramin.
Suramin inhibits Smad-3 phosphorylation in the remnant
kidney
TGF-betasignaling is associated with almost all forms of kidney
disease characterized by renal fibrosis and inflammation, and
smad-3 is a critical component of the intracellular pathway that
transmits TGF-beta signals from the cell surface into the nucleus
[44,45]. To determine whether suramin would have an inhibitory
effect on the TGF-beta signaling pathway, we examined the effect
of suramin on Smad-3 phosphorylation in the remnant kidney.
Fig. 9 shows that renal ablation induced Smad-3 phosphorylation,
which was suppressed by suramin administration. Phosphorylated
smad-3 was not detectable in the sham–operated kidney with/
without administration of suramin. Total Smad-3 expression was
the same in each group. Thus, suramin substantially blocked TGF-
beta signaling, which may mediate the antifibrotic effects of this
compound in the remnant kidney.
Discussion
Renal fibrosis is the final common pathway for most forms of
progressive renal disease and involves glomerular and vascular
sclerosis, and/or interstitial fibrosis. Most renal disorders (whether
glomerular or tubulointerstitial, congenital or acquired) lead to
renal fibrosis. Thus, there is a great interest in identifying and
developing drugs to prevent or reverse fibrosis. Recently, we
demonstrated that suramin inhibits activation and proliferation of
renal interstitial fibroblasts and attenuates the development of
renal interstitial fibrosis when given either immediately after injury
or3 daysafterinitiationofinjuryinUUOmodel[12,13], suggesting
itmaybeapotentialdrugfortreatmentoffibroticdisease.However,
it remains unclear whether suramin also improves glomerular and
vascular lesions as these pathological changes are not typical in
UUO model. As the remnant kidney is characterized by the slow
development of glomerulosclerosis, vascular sclerosis, tubulointer-
stitial fibrosis and renal inflammation [14,15], mimicking human
disease, we further tested the efficacy of suramin in this model. Our
results revealed that suramin administration is effective in
preventing the development of glomerular and vascular sclerosis
and attenuating inflammatory response.
To our knowledge, we are the first to demonstrate that suramin
exhibits a renoprotective effect in a model of hypertenisve
glomerulosclerosis. However, the mechanims by which suramin
protects against development of glomerulosclerosis are not fully
understood. Although blood pressure is an important factor
associated with this process [46], we recently observed renoprotec-
tion with suramin in the remnant kidney that was independent of
effects on systemic hypertension [12]. This indicates that suramin
may attenuate sclerosis through nonhemodynamic factors. Among
numerous nonhemodynamic factors, macrophages have been
shown to play an important pathogenic role in the progression of
glomerulosclerosis. For example, glomerular infiltration of mac-
rophages was observed within 1 to 2 wk of renal ablation, before
the development of renal scarring [47]. Glomerular macrophage
depletion by X-irradiation has been shown to ameliorate the
progression of the glomerular injury in the remnant kidney [15].
Further, macrophage-conditioned medium has been reported to
promote prosclerotic responses in cultured rat mesangial cells [48].
In the current study, we examined the effect of suramin on the
macrophage infiltration in the kidney and found that suramin
treatment significantly suppresed macrophage infiltration as
revealed by both histochemistry and immunoblot analysis. This
suggests that a reduction of macrophage by suramin may thus
have contributed to amelioration of sclerosis.
Suramin-mediated suppression of macrophage infiltration may
be through inhibition of chemokine expression. Previous studies
have indicated that production of MCP-1 and RANTES is able to
build up the chemokine gradient that serves as a chemotactic
signal to attract macrophages to the injured site in the kidney [49].
Figure 6. Effect of suramin on NF-kappaB activation in rat
remnant kidney. Kidney tissue lysates were subjected to immunoblot
analysis with specific antibodies against phospho-p65 NF-kappaB,
p65NF-kappaB. Expression levels of p-p65 NF-kappaB(B) were quanti-
fied by densitometry and normalized with p65 NF-kappaB. Data are
represented as the mean 6 S.E.M (n=6). Means with different
superscript letters are significantly different from one another (P,0.05).
doi:10.1371/journal.pone.0036194.g006
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and RANTES in the remnant kidney, and suramin treatment
significantly reduced their expression. Furthermore, suramin
inhibited renal ablation-induced phosphorylation of NF-kB, a
key transcriptional factor involved in the expression of multiple
proinflammatory chemokines and cytokines, including MCP-1
and RANTES. In addition, STAT3, another trancriptional factor,
is also highly phosphorylated in the remnant kidney, and its
phosphorylation is inhibited by suramin. This suggests that the
production of cytokines and chemokines in the damaged kidneys
can be transcriptionally regulated by both NF-kappaB and
STAT3. In support of this hypothesis, we have recently
demonstrated that the inhibition of STAT3 by S3I-201 suppressed
the expression of TNF-alpha, IL-1beta, and ICAM-1 without
affecting that of MCP-1 in the mouse kidney injured by ureteral
obstruction. Since NF-kappaB is well known to play an important
role in regulating MCP-1 expression [50], these findings suggest
that NF-kappaB and STAT3 can operate in concert to regulate
expression of cytokines and chemokines in injured kidneys.
It should be emphasized that NF-kappaB and STAT3 may
regulate expression not only of cytokines/chemokines, leading to
inflammatory responses, but also other genes involving renal
fibrogenesis. Recently, we reported that STAT3 activity is
required for the expression of TGF-beta1 and TGF-beta1 receptor
II [27]. NF-kappaB has also been shown to be able to interact
with AP-1 to regulate the expression of collagen, fibronectin
and TGF-beta1, enhancing ECM accumulation [51]. Notably,
AP-1 transcriptional factor is subjected to regulation by the
ERK1/2 signaling pathway, and suramin treatment also blocked
ERK1/2 phosphorylation in the remnant kidney. Therefore, it is
likely that suramin inhibits the inflammatory response in the
fibrotic kidney through multiple signaling pathways and transcrip-
tional factors.
It is well known that suramin exhibits its pharmacological effects
by interfering with the interaction of multiple growth factors/
cytokines and their receptors [5,6,7,8].. Previous studies have also
shown that suramin is a potent antagonist of PDGF, EGF and
TGF-beta receptors whereas activation of these three receptors is
Figure 7. Effect of suramin on phosphorylation of STAT3 and ERK1/2 in rat remnant kidney. (A) Kidney tissue lysates were subjected to
immunoblot analysis with specific antibodies against phospho-STAT3 (p-STAT3), STAT3, phospho-ERK1/2 (p-ERK1/2), ERK1/2. Expression levels of p-
STAT3 (B), STAT3 (C), p-ERK1/2 (D), ERK1/2 (E) were quantified by densitometry and normalized with GAPDH. Data are represented as the mean 6
S.E.M (n=6). Means with different superscript letters are significantly different from one another (P,0.05).
doi:10.1371/journal.pone.0036194.g007
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myofibroblasts, resulting in the production of excessive amount of
ECM proteins [52]. Thus, interference with these receptors by
suramin and subsequent blockade of signaling pathways initiated
from these receptors may be an important mechanism in
inhibiting renal fibroblast activation and attenuating production
of ECM proteins. Our studies in this model clearly demonstrated
that suramin treatment can abrogate phosphorylation of EGF and
PDGF receptors and reduce phosphorylation of Smad-3, a key
intracellular signaling molecule, downstream of TGF-betarecep-
tors, supporting its inhibitory effect on multiple profibrotic
receptors. These results are consistent with our observation in
the UUO model [12], providing a strong rationale to develop
suramin as a therapeutic intervention for fibrotic kidney disease.
Suramin has been used to treat selected malignancies and
metastatic diseases Our previous and current studies reveal that
suramin administration can attenuate interstitial fibrosis, reduce
glomerular and vascular injury, improve renal function and reduce
proteinuria [12]. Further, delayed administration of suramin was
also effective in attenuating the progression of renal fibrosis in
obstructive nephropathy [13]. Therefore, there is the potential
clinical application of suramin as an anti-fibrotic treatment in
patients with chronic kidney disease. As suramin is already
approved for use in humans, it would be possible to use it in
clinical studies in CKD to test its efficacy and safety in patients
with chronic kidney injury.
In summary, we have shown that suramin inhibits glomerular
and vascular sclerosis. The beneficial effects of suramin are linked
Figure 8. Effect of suramin on phosphorylation of PDGF receptor and EGF receptor in rat remnant kidney. (A) Kidney tissue lysates
were subjected to immunoblot analysis with specific antibodies against phospho-PDGF receptor-beta (p-PDGFR-beta), PDGF receptor, phospho-EGF
receptor (p-EGFR), EGF receptor (EGFR). Expression levels of p-PDGFR-beta(B), PDGFR-beta (C), p-EGFR (D), EGFR (E) were quantified by densitometry
and normalized with GAPDH. Data are represented as the mean 6 S.E.M (n=6). Means with different superscript letters are significantly different from
one another (P,0.05).
doi:10.1371/journal.pone.0036194.g008
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expression and inactivation of transcriptional factors. As renal
fibrogenesis is associated with the increased production of
numerous cytokines/growth factors and subsequent activation of
their receptors and signaling pathways, suramin with its ability to
inhibit the interaction of multiple cytokine/growth factor with
their receptors may offer improved therapeutic benefits in kidney
fibrotic diseases.
Materials and Methods
Chemicals and Antibodies
Antibodies to p-STAT3, STAT3, p-ERK1/2, ERK1/2, p-
EGFR, p-PDGFR-beta, PDGFR-beta, p-p65NF-kappaB, p65NF-
kappaB were purchased from Cell Signaling Technology (Dan-
vers, MA). Antibodies to GAPDH, EGFR, MCP-1, and RANTES
were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA). ED-1 antibody was purchased from Serotec (Oxford, UK).
Suramin and all other chemicals were from Sigma (St. Louis,
MO).
Remnant Kidney Models and Suramin Treatment
The remnant kidney model was created in male Sprague-
Dawley rats that weighed 180 to 200 g (Charles River Labora-
tories, Wilmington, MA). Five-sixths of normal renal mass was
surgically ablated according to our previous protocols [12]. Briefly,
20 animals underwent subtotal nephrectomy involving right
subcapsular nephrectomy and infarction of approximately two-
thirds of the left kidney by ligation of the posterior and one or two
anterior extra renal branches of the renal artery. In addition, 12
rats underwent a sham operation (laparotomy and manipulation of
the renal pedicles). On the second week after surgery, rats were
randomly divided into suramin treatment and non-treatment
groups. Suramin was given at 10 mg/kg once per week for two
weeks. 24-hour urine samples were collected in metabolic cages
starting at day 1 and weekly for the determination of urinary levels
of protein. 28 days after surgery, all animals were sacrificed and
the kidneys were then collected for further analysis.
Immunoblot Analysis
Immunoblot analysis of tissue samples was conducted as
described previously [53]. The densitometry analysis of immuno-
blot results was conducted by using NIH Image software (National
Institutes of Health, Bethesda, MD).
Immunohistochemical Staining
Immunohistochemical staining was performed according to the
procedure described in our previous studies [53]. ED1, MCP-1,
and RANTES staining were semi quantified by a computer-aided
morphometric analysis (MetaMorph; Universal Imaging Co.,
Downingtown, PA). Briefly, a grid containing 117 (13X9) sampling
points was superimposed on images of cortical high-power field
(6400). The number of grid points overlying positive area (except
tubular lumen and glomeruli) were counted and expressed as a
percentage of all sampling points, as described previously [27]. For
each kidney, 10 randomly selected, non-overlapping fields were
analyzed in a blinded manner.
Statistical Analysis
All the experiments were conducted at least three times. Data
depicted in graphs represent the means 6 SEM for each group.
Inter-group comparisons were made using one-way analysis of
variance (ANOVA). Multiple means were compared using Tukey’s
test. The differences between two groups were determined by
Student t-test. Statistical significant difference between mean
values was marked in each graph. P,0.05 is considered
significant.
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